Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
Enterprise Group (TSX: E), a company providing specialized equipment and services in the build-out of infrastructure for the energy, pipeline, and construction industries, announced a new business relationship with a Canadian based oil and gas producer secured by its Evolution Power projects division. It is another milestone for the company which continues to grow steadily, while providing a positive ROI to its investors.
In order to serve a wide range of clients, including small local businesses and Tier One global resource companies, Enterprise Group (TSX: E) aims to provide technologies that mitigate, reduce, or eliminate CO2 and greenhouse gas emissions. The 2004-founded company experienced phenomenal growth before going public in 2005 and graduating to the TSX only three years later, in 2007. The company, which has its attention on Western Canada, acquires companies to broaden its range of services, hasten organic growth, and cut costs. For Enterprise Group, its attractive growth profile preached is:
• Track record of successfully acquiring complementary businesses at accretive valuations and delivering results after the acquisition.
• Located in and along the foothills of the WCSB’s most productive areas, including the Oil Sands district and the Montney, Duvernay, Cardium, and Viking formations.
• Setting the bar higher by developing Natural Gas to Electricity methods of client-provided mobile power. helping their clients achieve their ESG goals by significantly reducing emissions, improving safety, and cutting costs.
Enterprise Group follows a 4-step process when buying a business:
Identification
• Successful privately owned businesses operating in their current markets and industries;
• Proven operational and financial performance serving select clients.
Evaluation
• Due to capital constraints, Target is unable to take advantage of growth opportunities;
• Is it possible to achieve a desirable transaction price?
Integration
• Use rewards to keep key executives.
• Find and use synergies with current business units;
• Invest money to support growth.
Growth
• Benefit from connections and practical knowledge;
• Expand opportunities, EBITDA, and revenue.
Here is an illustration of an effective acquisition: In 2007, Enterprise paid $12 million for TC Infrastructure, or a 2.0 multiple of trailing EBITDA. In 2016, the company sold TC for $20 million. TC generated $27 million in EBITDA for Enterprise Group during its ownership.
Enterprise Group announced on January 12 that its Evolution Power Projects division had established a new business connection with a Canadian oil and gas producer. The new client, valued at nearly $1 billion CAD, has a reputation for acquiring assets with exploitation potential while also putting in place a full-cycle exploration program. The company’s operational activities will be enhanced by the installation of natural gas power generation systems from Enterprise Group, helping it to better meet all environmental regulatory standards and requirements.
“We will continue to be early adopters of clean technology and industry innovation. We deliver value to our customers through emission reduction technology and support their ESG initiatives. Natural gas electrification is the future of energy evolution. Cleaner, quieter, safer, and most importantly – Measurable”
Heather Johnson, CEO of the EPP subsidiary
In order to “maintain and enhance the environmental quality of life for future generations,” the organization works to reduce its environmental impact. The way mobile power is supplied on-site is being reimagined by Evolution Power Projects. The targeted strategy aims to increase productivity, simplify rental management, support essential services, and promote natural gas substitutes. With the help of EPP’s “Concept to Completion Approach,” customers can assess their overall power needs, which also provides creative, low-carbon, environmentally friendly options.
The most recent financial statements were made for the period ending September 30, 2022. The business has no debt and $51.3M in total assets, including $1.6M in cash and $40.7M in property, plant, and equipment. Revenue for the third quarter of 2022 was $5.2M, an increase of 33% from the third quarter of 2021. This rise is comparable to the year-over-year rises in gross margin and adjusted gross margin. Compared to Q3 2021, the adjusted EBITDA increased by 16%. Enterprise Group spent $3.6M, and incurred a net loss of $677k, primarily due to the depreciation of property, plant, and equipment ($1M).
Enterprise Group has 52M shares outstanding, and has neither warrants nor options. Enterprise Group effects a Normal-Course Issuer Bid program and bought back +9M shares since inception. Now, the management team owns 40%, which is pretty massive.
The stock price, which has been hovering around $0.40, is essentially unchanged. The 52-week range is $0.28 to $0.46, but Fundamental Research’s analysis shows that the company’s valuation ought to be higher. Fundamental Research Research is maintaining its BUY recommendation and $1.08 per share fair value estimate. Future catalysts include the company’s mobile power systems being adopted more widely and strong Q4 results.
Enterprise Group (TSX: E) keeps expanding. Revenue growth is still visible in its financial reports, and the most recent partnership will increase gains. Enterprise Group is vastly undervalued, as shown by Fundamental Research, which in its report, estimated a fair value of $1.08 per share and noted that the company’s mobile power systems would support its growth during Q4 2022.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts